TCL Archive Advisors Clear Herceptin; Find Tamoxifen Indicated For “Short Term Risk Reduction” September 11, 1998
TCL Archive House Plan Promises $3.5 Billion For NIH; Cooperative Groups May Get AHRQ Funds January 23, 2009
TCL Archive European regulators plan more rigorous rules for accelerated approval in cancer. November 11, 2005
TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive New Chemoprevention Program Will Get “Whatever Money It Need;” Clinical Trials In New Division July 25, 1980
